Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.
G L Bray, A R Thompson
G L Bray, A R Thompson
Published April 1, 1986
Citation Information: J Clin Invest. 1986;77(4):1194-1200. https://doi.org/10.1172/JCI112421.
View: Text | PDF
Research Article

Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.

  • Text
  • PDF
Abstract

A partial gene product was identified in a pedigree with hemophilia B due to a partial deletion of the Factor IX gene (Chen, S.-H.,S. Yoshitake, P.F. Chance, G.L. Bray, A.R. Thompson, C.R. Scott, and K. Kurachi, 1985, J. Clin. Invest., 76:2161-2164). Levels of this mutant protein in plasma of affected family members studied ranged from 24 to 36 ng/ml (0.6-0.9 U/dl or percent of normal) by a solid-phase immunoassay which is sensitive and specific for the calcium-dependent conformation of human Factor IX. No Factor IX antigen could be detected in patients' plasmas by a non-calcium-requiring monoclonal anti-Factor IX antibody (less than 2 ng/ml). The unconcentrated urine from the five affected family members and four obligate heterozygotes the five affected family members and four obligate heterozygotes tested contained calcium-dependent Factor IX antigen levels ranging from 64 to 160 ng/ml (1.6-4.0 U/dl) and from 10 to 68 ng/ml (0.25-1.7 U/dl), respectively. Of nine normal volunteers screened, three had detectable calcium-dependent antigen in unconcentrated first morning-voided urines with 9.6-16.8 ng/ml (0.24-0.42 U/dl), while the remaining six had detectable urinary antigen only after a 10-fold concentration. Abnormal and normal urinary Factor IX antigen species were concentrated, immunoaffinity purified, electrophoresed, immunoblotted, and distinguished by autoradiography after incubation with 125I-polyclonal calcium-requiring anti-Factor IX. After reducing purified or concentrated samples, a single abnormal 36,000-mol-wt band was identified in the urines from the four affected family members and four obligate heterozygotes tested. Electrophoresis of the reduced urinary Factor IX antigen from the one normal subject tested showed a broad 15,000-20,000-mol-wt band. This normal band was smaller than the species in patients' urines, and was seen as a minor component in the samples from the heterozygotes. No abnormal antigen could be detected in urine from the two other female family members tested. Thus, abnormal urinary Factor IX antigen represents a marker for the presence of the hemophilic Factor IX gene in this family.

Authors

G L Bray, A R Thompson

×

Total citations by year

Year: 2012 2004 1991 1989 1988 1987 1969 Total
Citations: 1 1 1 2 2 5 1 13
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (13)

Title and authors Publication Year
Methods in Enzymology
JD Stone, AS Chervin, DH Aggen, DM Kranz
Protein Engineering for Therapeutics Part B 2012
Severe hemophilia A due to a 1.3 kb factor VIII gene deletion including exon 24: homologous recombination between 41 bp within an Alu repeat sequence in introns 23 and 24
SM Nakaya, TC Hsu, SJ Geraghty, MJ Manco-Johnson, AR Thompson
Journal of Thrombosis and Haemostasis 2004
Recombinant Technology in Hemostasis and Thrombosis
LW Hoyer, WN Drohan
1991
3 Factor IX
F Giannelli
Baillière's Clinical Haematology 1989
A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver
VA Geddes, BF Bonniec, GV Louie, GD Brayer, AR Thompson, RT MacGillivray
The Journal of biological chemistry 1989
The molecular basis of blood coagulation
B Furie, BC Furie
Cell 1988
Biotechnology in blood transfusion
CT Sibinga, PC Das, LR Overby
1988
Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients
RJ Matthews, DS Anson, IR Peake, AL Bloom
Journal of Clinical Investigation 1987
Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX
BG Schach, S Yoshitake, EW Davie
Journal of Clinical Investigation 1987
The Molecular Genetics of Hemophilia B
VA Geddes, RT MacGillivray
Transfusion Medicine Reviews 1987
Alloantibodies in hemophilia B binding to multiple factor IX epitopes
AR Thompson
Thrombosis Research 1987
The New Dimensions of Warfarin Prophylaxis
S Wessler, CG Becker, Y Nemerson
1987
Protides of the Biological Fluids
PA Small, RH Waldman
Protides of the Biological Fluids 1969

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts